Vihuma
simoctocog alfa · Octapharma AB
AUTHORISED IN THE EUWhat Vihuma is used for
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Vihuma can be used for all age groups.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Vihuma
- Active substance
- simoctocog alfa
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD02
- Marketing authorisation holder
- Octapharma AB
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vihuma used for?
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Vihuma can be used for all age groups.
What is the active substance in Vihuma?
Vihuma contains simoctocog alfa.
Who makes Vihuma?
The EU marketing authorisation holder is Octapharma AB.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU